마이크로바이옴 제휴 및 라이선싱 계약(2016-2026년)

The definitive benchmark for microbiome dealmaking

Microbiome partnering is driven by emerging science and novel therapeutic approaches, with deal structures reflecting platform-based technologies, live biotherapeutics, and data-driven discovery.

This report provides a comprehensive and structured analysis of 250+ microbiome collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how microbiome deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by platform type, application, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly innovative and still-evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within microbiome partnerships, particularly in areas involving novel mechanisms of action and emerging clinical validation.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark emerging technology transactions
• Prepare for negotiations with well-defined market context
• Evaluate platform partnerships and collaboration opportunities
• Support internal strategy with robust, defensible data
• What's included
• 250+ microbiome collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, platform, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for microbiome dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how microbiome partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in microbiome dealmaking

• 2.1. Introduction
• 2.2. Microbiome deals over the years
• 2.3. Most active microbiome dealmakers
• 2.4. Microbiome deals by deal type
• 2.5. Microbiome deals by therapy area
• 2.6. Microbiome deals by industry sector
• 2.7. Deal terms for microbiome deals
  • 2.7.1 Microbiome deals headline values
  • 2.7.2 Microbiome deal upfront payments
  • 2.7.3 Microbiome deal milestone payments
  • 2.7.4 Microbiome royalty rates

Chapter 3 - Leading microbiome deals

• 3.1. Introduction
• 3.2. Top microbiome deals by value

Chapter 4 - Most active microbiome dealmakers

• 4.1. Introduction
• 4.2. Most active microbiome dealmakers
• 4.3. Most active microbiome deals company profiles

Chapter 5 - Microbiome contracts dealmaking directory

• 5.1. Introduction
• 5.2. Microbiome contracts dealmaking directory

Chapter 6 - Microbiome dealmaking by technology type

• Deal directory
• Deal directory - Microbiome deals by company A-Z
• Deal directory - Microbiome deals by deal type
• Deal directory - Microbiome deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Microbiome deals since 2016
• Figure 2: Active microbiome dealmaking activity since 2016
• Figure 3: Microbiome deals by deal type since 2016
• Figure 4: Microbiome deals by therapy area since 2016
• Figure 5: Microbiome deals by industry sector since 2016
• Figure 6: Microbiome deals with a headline value
• Figure 7: Microbiome deals with an upfront value
• Figure 8: Microbiome deals with a milestone value
• Figure 9: Microbiome deals with a royalty rate value
• Figure 10: Top microbiome deals by value since 2016
• Figure 11: Most active microbiome dealmakers since 2016
• Figure 12: Microbiome deals by technology type since 2016